38 results
8-K
EX-99.1
RETA
Reata Pharmaceuticals Inc
23 Jul 18
Other Events
7:00am
adverse events have generally been mild to moderate in intensity. Twenty-five patients were available for the analysis, and no discontinuations were due … were reported, and the reported adverse events were generally mild to moderate in intensity. Twenty-eight patients were available for the analysis
8-K
EX-99.2
RETA
Reata Pharmaceuticals Inc
23 Jul 18
Other Events
7:00am
events No drug-related SAEs, changes in blood pressure, or fluid overload-events AEs have been generally mild to moderate in intensity Most commonly … generally mild to moderate in intensity Most commonly reported AE is muscle spasms Associated with reductions in CK No changes in blood pressure or fluid
8-K
EX-99.2
RETA
Reata Pharmaceuticals Inc
10 May 23
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial
6:45am
, pregabalin, gabapentin) Must not have achieved adequate pain control upon entry with NPRS pain intensity score ≥ 4 on a 0-10 point scale at screening … Primary endpoint: Change in average pain intensity assessed by NPRS at Week 12 Plan to initiate the study in Q3 2023
Bardoxolone Update
AYAME
8-K
EX-99.1
RETA
Reata Pharmaceuticals Inc
25 Sep 18
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl In Iga Nephropathy and Type 1 Diabetic Chronic Kidney Disease
7:05am
, and the reported adverse events were generally mild to moderate in intensity.
“With these data, bardoxolone has improved kidney function in multiple rare
8-K
EX-99.1
RETA
Reata Pharmaceuticals Inc
25 May 18
Other Events
6:03am
adverse events have generally been mild to moderate in intensity. Full data for the primary endpoint of change in eGFR at Week 12 for the ADPKD, IgA
8-K
EX-99.2
cd0tqfz8 z9rkord
25 May 18
Other Events
6:03am
8-K
EX-99.1
cmvex2j8
15 Oct 19
Reata announces positive Topline results from the moxie Registrational trial of omaveloxolone in patients with friedreich’s ataxia
6:45am
8-K
EX-99.2
byr024o
15 Oct 19
Reata announces positive Topline results from the moxie Registrational trial of omaveloxolone in patients with friedreich’s ataxia
6:45am
8-K
EX-99.2
pe1f4
12 Nov 19
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs
6:50am
8-K
EX-99.2
dyv5lw3c86twwut7v24
25 Sep 18
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl In Iga Nephropathy and Type 1 Diabetic Chronic Kidney Disease
7:05am
8-K
EX-99.3
v46td8d8uwl0r
25 May 18
Other Events
6:03am
8-K
EX-99.2
vpr n7bc3uooj3
9 Nov 20
Reported positive year 2 data from the pivotal CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome
6:51am
8-K
EX-99.1
zx5vs
11 Jan 21
Regulation FD Disclosure
6:30am
8-K
EX-99.1
m8f5r2lnf toyu42sdr
9 Nov 20
Vinny Jindal; Reata Pharmaceuticals Inc.; VP of Strategy
5:30pm
424B5
fs0ozh
14 Nov 19
Prospectus supplement for primary offering
4:36pm
424B5
efjcac
12 Nov 19
Prospectus supplement for primary offering
5:15pm